Navamedic ASA (OSL:NAVA)

Market Cap	520.40M
Revenue (ttm)	539.42M
Net Income (ttm)	-37.89M
Shares Out	23.98M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	54.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,520
Average Volume	30,405
Open	22.20
Previous Close	22.00
Day's Range	21.70 - 22.20
52-Week Range	17.10 - 27.90
Beta	0.24
RSI	45.27
Earnings Date	Feb 12, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.